Phathom Pharmaceuticals Inc Cash Flow Conversion Efficiency
Phathom Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Phathom Pharmaceuticals Inc (PHAT) has a cash flow conversion efficiency ratio of 0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.12 Million) by net assets ($-422.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Phathom Pharmaceuticals Inc (2018–2024)
Cash flow conversion efficiency of Phathom Pharmaceuticals Inc from 2018 to 2024. This chart illustrates how Phathom Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PHAT live share price for real-time trading data and today's change.
Phathom Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Phathom Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Phathom Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Phathom Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Phathom Pharmaceuticals Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Indigo Paints Limited
NSE:INDIGOPNTS
|
0.027x |
|
Lanzhou Minbai Shareholding Group Co Ltd
SHG:600738
|
0.017x |
|
Barnes & Noble Education Inc
NYSE:BNED
|
0.274x |
|
DNA Link Inc
KQ:127120
|
-0.060x |
|
Ackerstein Group Ltd
TA:ACKR
|
0.042x |
|
Triductor Technology (Suzhou) Inc.
SHG:688259
|
0.022x |
|
Grupo Supervielle SA
NYSE:SUPV
|
-0.378x |
|
Banestes S.A - Banco do Estado do Espírito Santo
SA:BEES3
|
-1.747x |
Annual Cash Flow Conversion Efficiency for Phathom Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Phathom Pharmaceuticals Inc from 2018 to 2024. Review Phathom Pharmaceuticals Inc financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-253.58 Million | $-266.77 Million | 1.052x | -44.36% |
| 2023-12-31 | $-72.76 Million | $-137.58 Million | 1.891x | -3.46% |
| 2022-12-31 | $-74.81 Million | $-146.53 Million | 1.959x | +195.20% |
| 2021-12-31 | $72.16 Million | $-148.46 Million | -2.057x | -473.56% |
| 2020-12-31 | $194.27 Million | $-69.69 Million | -0.359x | -123.97% |
| 2019-12-31 | $227.96 Million | $-36.51 Million | -0.160x | -120.13% |
| 2018-12-31 | $-1.29 Million | $-1.02 Million | 0.795x | -- |
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical t… Read more